TP53 and neoplasm: In the tumor biopsy cohort before CTx, patients with MSI-H tumors showed a better OS compared to the MSS/EBV− tumors only in the p53 wild-type group (median MSI-H not reached, MSS/EBV− 44.6 months), whereas an even worse OS for MSI-H compared to MSS/EBV− tumors was observed in the presence of aberrant p53 expression (median MSI-H 23.4 months, MSS/EBV− 36.6 months, overall p log rank = 0.414).